8-K 1 d761443d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 11, 2019

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

 

 

 

Israel   001-16174   Not Applicable
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

5 Basel Street

P.O. Box 3190

Petach Tikva 4951033, Israel

(Address of Principal Executive Offices, including Zip Code)

+972-3-914-8171

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

American Depositary Shares, each representing one Ordinary Share   TEVA   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐

Emerging Growth Company

 

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

ITEM 5.07

Submission of Matters to a Vote of Security Holders

 

(a)

Teva Pharmaceutical Industries Limited (“Teva”) held its Annual Meeting of Shareholders on June 11, 2019 (the “Annual Meeting”).

 

(b)

The following is a summary of the matters voted on at that meeting.

 

  (1)

The shareholders elected the following directors to serve on Teva’s Board of Directors (the “Board”), until Teva’s 2022 annual meeting of shareholders, as follows:

 

Directors    For      Against      Abstain      Brokers
non-vote		  

Amir Elstein

      633,473,295        21,948,152        1,354,997        137,078,223  

Roberto A. Mignone

      642,834,352        12,974,599        967,493        137,078,223  

Dr. Perry D. Nisen

      642,929,707        12,907,677        939,060        137,078,223  

 

  (2)

The shareholders approved, on a non-binding advisory basis, the compensation for Teva’s named executive officers listed in the proxy statement for the Annual Meeting, as follows:

 

For    Against      Abstain      Brokers non-vote  
581,375,822      72,465,583        1,575,643        137,078,223  

 

  (3)

The shareholders approved an amended Compensation Policy with respect to the terms of office and employment of Teva’s Executive Officers and Directors, as follows:

 

     For      Against      Abstain      Brokers non-vote  

Indicating “YES” for personal interest

      11,178,218        10,385,135        720,505        —    

Indicating “NO” for personal interest

      561,922,187        55,989,678        592,579        —    

Total

      573,100,405        66,374,813        1,313,084        137,078,223  

 

  (4)

Director Compensation:

 

  a.

The shareholders approved the compensation to be provided to Teva’s non-employee directors, as follows:

 

For    Against      Abstain      Brokers non-vote  
518,694,561      136,907,171        1,173,482        137,078,223  

 

  b.

The shareholders approved the compensation to be provided to Teva’s non-executive Chairman of the Board, as follows:

 

For    Against      Abstain      Brokers non-vote  
533,967,862      121,659,408        1,149,174        137,078,223  

 

  (5)

The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2020 annual meeting of shareholders, as follows:

 

For    Against      Abstain      Brokers non-vote  
773,992,867      15,821,278        1,846,305        —    

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: June 11, 2019     By:  

/s/ Michael McClellan

      Name:   Michael McClellan
      Title:   Executive Vice President, Chief
        Financial Officer